Table 2.

Characteristics of Patients With HoFH Dichotomized According to Age at Diagnosis

	Age <15 y (n = 47)	Age ≥15 y (n = 92)	P Value
Male	18 (38)	41 (45)	0.60
Age at assessments, y	46 ± 17	57 ± 13	<0.001
Body mass index, kg/m2	23.8 ± 4.9	24.5 ± 4.1	0.37
Systolic blood pressure, mm Hg	119 ± 15	127 ± 16	0.009
Diastolic blood pressure, mm Hg	66 ± 13	71 ± 12	0.03
Heart rate, beats/min	70 ± 9	71 ± 10	0.94
Family history	44 (98)	75 (93)	0.42
Age at diagnosis, y	0.0 (0.0-4.5)	40.5 (25.0-52.0)	<0.001
Cutaneous xanthoma	32 (68)	48 (53)	0.14
Tendon xanthoma	43 (92)	66 (73)	0.02
Achilles tendon thickness, mm	19.05 (14.26)	16.81 (7.67)	0.31
Achilles tendon thickness ≥9 mm	38 (100)	58 (95)	0.43
Valvular disease	16 (34)	24 (26)	0.43
Aortic valvular disease	17 (71)	11 (69)
Coronary artery disease	28 (61)	66 (73)	0.23
Prior PCI	12 (38)	44 (62)	0.04
Prior CABG	11 (36)	15 (23)	0.28
Carotid arteriosclerosis	30 (65)	47 (53)	0.26
Arcus corneae	19 (44)	28 (32)	0.23
Total cholesterol before medication, mmol/L	12.84 ± 3.27	12.16 ± 2.57	0.28
Triglycerides before medication, mmol/L	1.28 ± 0.60	1.97 ± 1.34	0.01
HDL cholesterol before medication, mmol/L	1.22 ± 0.41	1.53 ± 1.35	0.25
LDL cholesterol before medication, mmol/L	10.56 ± 2.84	9.89 ± 2.14	0.20
Genetic testing	28 (61)	18 (20)	<0.001
Diagnosis			0.001
Definite	24 (51)	19 (21)
Probable	23 (49)	73 (79)
Lipoprotein apheresis	19 (40)	12 (13)	0.001
Statin	44 (94)	90 (99)	0.22
High-intensity statina	37 (79)	69 (75)	0.78
Ezetimibe	36 (78)	62 (68)	0.30
PCSK9 inhibitors	21 (45)	44 (48)	0.86

Values are n (%), mean ± SD, or median (IQR) unless otherwise indicated.

Abbreviations as in Table 1.

^aIn this study, statin doses ≥20 mg atorvastatin, 4 mg pitavastatin, or 10 mg rosuvastatin were considered as high-intensity statin therapy.